ACRS
Aclaris Therapeutics, Inc.
There isn't enough reported data to score ACRS yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ACRS Fundamentals
| Metric | Status |
|---|---|
| Weak | |
| Weak | |
| Weak | |
| Unavailable |
ACRS's revenue, profitability and cash flow are currently weak. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ACRS PE Valuation
ACRS has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ACRS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses steady | |
| Decline | |
| -- | |
| Limited | |
| Low |
Analysts expect ACRS's revenue to decline, with its earnings and profitability holding steady. However, they disagree widely on these estimates.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ACRS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.58 | +$1.00 |
| Q2 2026 | -$0.58 | +$0.99 |
| Q1 2026 | -$0.56 | +$1.03 |
| Q4 2025 | -$0.53 | +$1.18 |
| Q3 2025 | -$1.58 | -$1.06 |
| Q2 2025 | -$1.57 | -$0.75 |
| Q1 2025 | -$1.59 | -$0.50 |
| Q4 2024 | -$1.71 | -$0.44 |
ACRS is still losing money, but far less than before: $0.58 per share over the past year, against $3.90 at its worst in late 2019.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ACRS on earnings quality, reporting a profit while its opponent remains loss making.
ACRS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5M | -55% |
| Q2 2026 | $1.6M | -8.3% |
| Q1 2026 | $2M | +37% |
| Q4 2025 | $1.3M | -86% |
| Q3 2025 | $3.3M | -24% |
| Q2 2025 | $1.8M | -36% |
| Q1 2025 | $1.5M | -39% |
| Q4 2024 | $9.2M | -48% |
ACRS's revenue has slid since its 2022 peak: $1M last quarter, down 55% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -1441% | -921 points |
| Q2 2026 | -1488% | -452 points |
| Q1 2026 | -1112% | +131 points |
| Q4 2025 | -1756% | -673 points |
| Q3 2025 | -520% | -279 points |
| Q2 2025 | -1036% | -571 points |
| Q1 2025 | -1243% | -453 points |
| Q4 2024 | -1082% | -1059 points |
ACRS's operating margin was −1441% last quarter, down 921 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ACRS on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ACRS on profitability, with a higher operating margin.
ACRS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$24.1M | -$13.1M |
| Q2 2026 | -$19.9M | -$9.9M |
| Q1 2026 | -$18.2M | -$5.1M |
| Q4 2025 | -$13.2M | -$4.2M |
| Q3 2025 | -$11M | -150% |
| Q2 2025 | -$10M | +$2.3M |
| Q1 2025 | -$13.1M | +$7.9M |
| Q4 2024 | -$8.9M | -$1.7M |
ACRS has burned cash in almost every quarter: −$75M over the past year, against −$43M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ACRS on cash generation, producing positive trailing cash flow while its opponent burns cash.
ACRS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +4.7% | +6.7M shares |
| 1 year | +22% | +26.8M shares |
| 3 years | +112% | +78.8M shares |
| 5 years | +177% | +95.5M shares |
| Available history | +262% | +108M shares |
ACRS has 149M diluted shares, up 22% from a year ago.
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ACRS on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ACRS Net Leverage
ACRS's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ACRS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 43.9 | Neutral |
| Stochastic | 22.7 | Neutral |
ACRS's weekly RSI is 44 (neutral) and its Stochastic is 23 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ACRS PE vs Healthcare Sector
ACRS has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ACRS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $4.03 | 0.7% below |
| 20 week MA | $5.03 | 20% below |
| 50 week MA | $4.27 | 6.3% below |
| 100 week MA | $3.09 | 29% above |
| 200 week MA | $3.91 | 2.3% above |
ACRS has slipped below its 8-, 20- and 50-week averages, though it's still 2.3% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ACRS on trend strength, trading above more of its moving averages.
ACRS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $1.92 | $7.61 | +296% |
| 2021 | $7.61 | $15.4 | +103% |
| 2022 | $15.4 | $15.1 | -2.3% |
| 2023 | $15.1 | $1.05 | -93% |
| 2024 | $1.05 | $2.73 | +160% |
| 2025 | $2.73 | $3.03 | +11% |
| 2026 YTD | $3.03 | $4.00 | +32% |
ACRS's yearly returns have swung widely, from +296% in 2020 to −93% in 2023. It's up 32% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over ACRS on returns for 2026, with the stronger performance.